83 related articles for article (PubMed ID: 36615606)
21. Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.
Garrido MP; Fredes AN; Lobos-González L; Valenzuela-Valderrama M; Vera DB; Romero C
Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052757
[TBL] [Abstract][Full Text] [Related]
22. The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
Murphy AD; Morgan RD; Clamp AR; Jayson GC
Br J Cancer; 2022 Apr; 126(6):851-864. PubMed ID: 34716396
[TBL] [Abstract][Full Text] [Related]
23. Folate receptor-mediated delivery of 1-MDT-loaded mesoporous silica magnetic nanoparticles to target breast cancer cells.
Hashemzadeh N; Dolatkhah M; Aghanejad A; Barzegar-Jalali M; Omidi Y; Adibkia K; Barar J
Nanomedicine (Lond); 2021 Oct; 16(24):2137-2154. PubMed ID: 34530630
[No Abstract] [Full Text] [Related]
24. Ultrasound Responsive Magnetic Mesoporous Silica Nanoparticle-Loaded Microbubbles for Efficient Gene Delivery.
Du M; Chen Y; Tu J; Liufu C; Yu J; Yuan Z; Gong X; Chen Z
ACS Biomater Sci Eng; 2020 May; 6(5):2904-2912. PubMed ID: 33463299
[No Abstract] [Full Text] [Related]
25. Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease.
Arend RC; Jackson-Fisher A; Jacobs IA; Chou J; Monk BJ
Cancer Biol Ther; 2021 Feb; 22(2):89-105. PubMed ID: 33427569
[TBL] [Abstract][Full Text] [Related]
26. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.
Fu Z; Xiang J
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266216
[TBL] [Abstract][Full Text] [Related]
27. Saponins Extracted from Tea (
Wang Y; Xia C; Chen L; Chen YC; Tu Y
Molecules; 2020 Nov; 25(22):. PubMed ID: 33187244
[TBL] [Abstract][Full Text] [Related]
28. Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery.
Li M; Zhao G; Su WK; Shuai Q
Front Chem; 2020; 8():647. PubMed ID: 32850662
[TBL] [Abstract][Full Text] [Related]
29. Wogonin Induces Apoptosis and Reverses Sunitinib Resistance of Renal Cell Carcinoma Cells
Wang Y; Chen S; Sun S; Liu G; Chen L; Xia Y; Cui J; Wang W; Jiang X; Zhang L; Zhu Y; Zou Y; Shi B
Front Pharmacol; 2020; 11():1152. PubMed ID: 32792963
[TBL] [Abstract][Full Text] [Related]
30. The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life.
Reid F; Bhatla N; Oza AM; Blank SV; Cohen R; Adams T; Benites A; Gardiner D; Gregory S; Suzuki M; Jones A
Int J Gynecol Cancer; 2021 Feb; 31(2):238-244. PubMed ID: 32540894
[TBL] [Abstract][Full Text] [Related]
31. MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer.
Haque A; Sait KHW; Alam Q; Alam MZ; Anfinan N; Wali AWN; Rasool M
Front Genet; 2020; 11():516. PubMed ID: 32528530
[TBL] [Abstract][Full Text] [Related]
32. Unraveling Determinants of Affinity Enhancement in Dimeric Aptamers for a Dimeric Protein.
Manochehry S; McConnell EM; Li Y
Sci Rep; 2019 Nov; 9(1):17824. PubMed ID: 31780794
[TBL] [Abstract][Full Text] [Related]
33. Preparation, characterizations and in vitro cytotoxic activity of nickel oxide nanoparticles on HT-29 and SW620 colon cancer cell lines.
Khan S; Ansari AA; Malik A; Chaudhary AA; Syed JB; Khan AA
J Trace Elem Med Biol; 2019 Mar; 52():12-17. PubMed ID: 30732872
[TBL] [Abstract][Full Text] [Related]
34. Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients.
Czogalla B; Kahaly M; Mayr D; Schmoeckel E; Niesler B; Kolben T; Burges A; Mahner S; Jeschke U; Trillsch F
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597961
[TBL] [Abstract][Full Text] [Related]
35. Silicon nanodot-based aptasensor for fluorescence turn-on detection of mucin 1 and targeted cancer cell imaging.
Zhang Y; Guo S; Huang H; Mao G; Ji X; He Z
Anal Chim Acta; 2018 Dec; 1035():154-160. PubMed ID: 30224134
[TBL] [Abstract][Full Text] [Related]
36. Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances.
Narayan R; Nayak UY; Raichur AM; Garg S
Pharmaceutics; 2018 Aug; 10(3):. PubMed ID: 30082647
[TBL] [Abstract][Full Text] [Related]
37. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells.
Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H
Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514
[TBL] [Abstract][Full Text] [Related]
38. pH-controlled sunitinib anticancer release from magnetic chitosan nanoparticles crosslinked with κ-carrageenan.
Karimi MH; Mahdavinia GR; Massoumi B
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():705-714. PubMed ID: 30033305
[TBL] [Abstract][Full Text] [Related]
39. Fabrication of acetylated carboxymethylcellulose coated hollow mesoporous silica hybrid nanoparticles for nucleolin targeted delivery to colon adenocarcinoma.
Nejabat M; Mohammadi M; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Carbohydr Polym; 2018 Oct; 197():157-166. PubMed ID: 30007600
[TBL] [Abstract][Full Text] [Related]
40. Mucin-1 aptamer-armed superparamagnetic iron oxide nanoparticles for targeted delivery of doxorubicin to breast cancer cells.
Aghanejad A; Babamiri H; Adibkia K; Barar J; Omidi Y
Bioimpacts; 2018; 8(2):117-127. PubMed ID: 29977833
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
